133 related articles for article (PubMed ID: 21489973)
1. The risk of serious infections in patients receiving anakinra for rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.
Galloway JB; Hyrich KL; Mercer LK; Dixon WG; Watson KD; Lunt M; ; Symmons DP;
Rheumatology (Oxford); 2011 Jul; 50(7):1341-2. PubMed ID: 21489973
[No Abstract] [Full Text] [Related]
2. Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register.
Dixon WG; Watson K; Lunt M; Hyrich KL; Silman AJ; Symmons DP;
Arthritis Rheum; 2006 Aug; 54(8):2368-76. PubMed ID: 16868999
[TBL] [Abstract][Full Text] [Related]
3. Anakinra delayed skin allergy expressing as both injection site reactions and generalized exanthema.
Lungoci ER; Hacard F; Nicolas JF; Berard F
Eur J Dermatol; 2015; 25(5):503-4. PubMed ID: 26575828
[No Abstract] [Full Text] [Related]
4. British Society for Rheumatology Biologics Register.
Silman A; Symmons D; Scott DG; Griffiths I
Ann Rheum Dis; 2003 Nov; 62 Suppl 2(Suppl 2):ii28-9. PubMed ID: 14532144
[TBL] [Abstract][Full Text] [Related]
5. Influence of anti-tumor necrosis factor therapy on cancer incidence in patients with rheumatoid arthritis who have had a prior malignancy: results from the British Society for Rheumatology Biologics Register.
Dixon WG; Watson KD; Lunt M; Mercer LK; Hyrich KL; Symmons DP; ;
Arthritis Care Res (Hoboken); 2010 Jun; 62(6):755-63. PubMed ID: 20535785
[TBL] [Abstract][Full Text] [Related]
6. Serious infection across biologic-treated patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis.
Rutherford AI; Subesinghe S; Hyrich KL; Galloway JB
Ann Rheum Dis; 2018 Jun; 77(6):905-910. PubMed ID: 29592917
[TBL] [Abstract][Full Text] [Related]
7. Occurrence of Rheumatoid Arthritis in a Patient Treated with Anakinra for Schnitzler Syndrome: A Case Report.
Margerin F; Gottenberg JE; Lipsker D
J Rheumatol; 2016 Jul; 43(7):1447. PubMed ID: 27371651
[No Abstract] [Full Text] [Related]
8. A randomised trial evaluating anakinra in early active rheumatoid arthritis.
Scott IC; Ibrahim F; Simpson G; Kowalczyk A; White-Alao B; Hassell A; Plant M; Richards S; Walker D; Scott DL
Clin Exp Rheumatol; 2016; 34(1):88-93. PubMed ID: 26842950
[TBL] [Abstract][Full Text] [Related]
9. Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials.
Salliot C; Dougados M; Gossec L
Ann Rheum Dis; 2009 Jan; 68(1):25-32. PubMed ID: 18203761
[TBL] [Abstract][Full Text] [Related]
10. Good response to infliximab in rheumatoid arthritis following failure of interleukin-1 receptor antagonist.
Bao J; Yue T; Li T; He DY; Bao YX
Int J Rheum Dis; 2016 Apr; 19(4):370-6. PubMed ID: 24798350
[TBL] [Abstract][Full Text] [Related]
11. Impact of Etanercept Therapy on Disease Activity and Health-Related Quality of Life in Moderate Rheumatoid Arthritis Patients Population from a National British Observational Cohort.
Kotak S; Mardekian J; Horowicz-Mehler N; Shah A; Burgess A; Kim J; Gemmen E; Boyd H; Koenig A
Value Health; 2015 Sep; 18(6):817-23. PubMed ID: 26409609
[TBL] [Abstract][Full Text] [Related]
12. Recurrent serious infections in patients with rheumatoid arthritis-results from the British Society for Rheumatology Biologics Register.
Subesinghe S; Rutherford AI; Byng-Maddick R; Leanne Hyrich K; Benjamin Galloway J
Rheumatology (Oxford); 2018 Apr; 57(4):651-655. PubMed ID: 29340619
[TBL] [Abstract][Full Text] [Related]
13. A network meta-analysis of randomized controlled trials of biologics for rheumatoid arthritis: a Cochrane overview.
Singh JA; Christensen R; Wells GA; Suarez-Almazor ME; Buchbinder R; Lopez-Olivo MA; Ghogomu ET; Tugwell P
CMAJ; 2009 Nov; 181(11):787-96. PubMed ID: 19884297
[TBL] [Abstract][Full Text] [Related]
14. The clinical and cost-effectiveness of anakinra for the treatment of rheumatoid arthritis in adults: a systematic review and economic analysis.
Clark W; Jobanputra P; Barton P; Burls A
Health Technol Assess; 2004 May; 8(18):iii-iv, ix-x, 1-105. PubMed ID: 15130461
[TBL] [Abstract][Full Text] [Related]
15. A meta-analysis of biologic therapies on risk of new or recurrent cancer in patients with rheumatoid arthritis and a prior malignancy.
Xie W; Xiao S; Huang Y; Sun X; Gao D; Ji L; Li G; Zhang Z
Rheumatology (Oxford); 2020 May; 59(5):930-939. PubMed ID: 31620795
[TBL] [Abstract][Full Text] [Related]
16. [The safety of interleukin-1 receptor antagonist (anakinra) in the treatment of rheumatoid arthritis].
Riente L
Reumatismo; 2004; 56(1 Suppl 1):74-9. PubMed ID: 15201943
[TBL] [Abstract][Full Text] [Related]
17. Effect of anakinra on functional status in patients with active rheumatoid arthritis receiving concomitant therapy with traditional disease modifying antirheumatic drugs: evidence from the OMEGA Trial.
Le Loët X; Nordström D; Rodriguez M; Rubbert A; Sarzi-Puttini P; Wouters JM; Woolley JM; Wright N; Lawrence C; Appleton B
J Rheumatol; 2008 Aug; 35(8):1538-44. PubMed ID: 18634163
[TBL] [Abstract][Full Text] [Related]
18. Anakinra for the treatment of rheumatoid arthritis: a safety evaluation.
Ramírez J; Cañete JD
Expert Opin Drug Saf; 2018 Jul; 17(7):727-732. PubMed ID: 29883212
[TBL] [Abstract][Full Text] [Related]
19. Safety of extended treatment with anakinra in patients with rheumatoid arthritis.
Fleischmann RM; Tesser J; Schiff MH; Schechtman J; Burmester GR; Bennett R; Modafferi D; Zhou L; Bell D; Appleton B
Ann Rheum Dis; 2006 Aug; 65(8):1006-12. PubMed ID: 16396977
[TBL] [Abstract][Full Text] [Related]
20. [Anakinra, a recombinant human IL-1 receptor antagonist, in clinical practice. Outcome in 60 patients with severe rheumatoid arthritis].
Botsios C; Sfriso P; Furlan A; Ostuni P; Biscaro M; Fiocco U; Todesco S; Punzi L
Reumatismo; 2007; 59(1):32-7. PubMed ID: 17435840
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
